US COVID Vaccine Authorizations: Too Much – Or Never Enough?
Executive Summary
A US FDA advisory committee review of a novel COVID vaccine candidate from Novavax made one thing very clear: The agency is firmly convinced that when it comes to vaccine options, more is better.